MIPH Stock Overview
MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
MINAPHARM Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م236.27 |
| 52 Week High | ج.م252.00 |
| 52 Week Low | ج.م128.50 |
| Beta | 0.13 |
| 1 Month Change | 15.83% |
| 3 Month Change | 18.64% |
| 1 Year Change | 69.11% |
| 3 Year Change | 193.50% |
| 5 Year Change | 179.61% |
| Change since IPO | 2,498.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| MIPH | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 0.9% |
| 1Y | 69.1% | 20.2% | 71.5% |
Return vs Industry: MIPH exceeded the EG Pharmaceuticals industry which returned 20.2% over the past year.
Return vs Market: MIPH underperformed the EG Market which returned 71.5% over the past year.
Price Volatility
| MIPH volatility | |
|---|---|
| MIPH Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in EG Market | 10.0% |
| 10% least volatile stocks in EG Market | 4.5% |
Stable Share Price: MIPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MIPH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | n/a | Wafik El Bardissi | https://www.minapharm.com |
MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Corneregel fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Netophtiole plus eye drops; Extrauma cream; and Ophtatrov and Optatrov plus. It also provides Ferroduonal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, Pixcolt, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules.
MINAPHARM Pharmaceuticals Fundamentals Summary
| MIPH fundamental statistics | |
|---|---|
| Market Cap | ج.م2.61b |
| Earnings (TTM) | ج.م460.73m |
| Revenue (TTM) | ج.م4.00b |
5.7x
P/E Ratio0.7x
P/S RatioIs MIPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIPH income statement (TTM) | |
|---|---|
| Revenue | ج.م4.00b |
| Cost of Revenue | ج.م2.40b |
| Gross Profit | ج.م1.60b |
| Other Expenses | ج.م1.14b |
| Earnings | ج.م460.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 41.64 |
| Gross Margin | 39.98% |
| Net Profit Margin | 11.51% |
| Debt/Equity Ratio | 90.8% |
How did MIPH perform over the long term?
See historical performance and comparison